Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Input metadata referenced "Altimmune," but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: PharmAthene is a biopharmaceutical company focused on developing biodefense countermeasures against biological and chemical weapons. The company has no commercial products and relies on U.S. government contracts and grants for revenue. Key product candidates include SparVax (anthrax vaccine), Valortim (anthrax monoclonal antibody), Protexia (nerve agent protectant), and RypVax (plague vaccine).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
Six Months Ended June 30, 2008 |
|---|---|---|---|
| Contract Revenue | $8.07 million | $13.59 million | $17.52 million |
| Net Loss | $(6.63) million | $(12.64) million | $(26.34) million |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.47) | $(1.19) |
| Cash and Cash Equivalents (Balance Sheet) |
$9.27 million (as of June 30, 2009) | ||
| Total Assets | $43.02 million (as of June 30, 2009) | ||
| Total Liabilities | $32.69 million (as of June 30, 2009) | ||
| Stockholders' Equity | $10.33 million (as of June 30, 2009) | ||
| Net Cash Used in Operating Activities | $(13.42) million (Six months 2009) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 31% for the three months and 22% for the six months ended June 30, 2009, compared to 2008. This was primarily due to a shift in the Protexia program from pre-clinical to clinical phases (lower costs) and reduced activity in the RypVax plague vaccine program.
- Improved Net Loss: Net loss improved significantly year-over-year (from $26.3M to $12.6M for the six-month period). The 2008 period included a one-time $15.9 million charge for acquired in-process research and development (IPR&D) related to the Avecia Acquisition, which did not recur in 2009.
- Derivative Liability Gains: The company recognized a gain of $0.76 million in the six months ended June 30, 2009, due to changes in the fair value of derivative instruments (warrants reclassified as liabilities under new accounting guidance).
- Liquidity Position: Cash and cash equivalents decreased by approximately $10.5 million during the six-month period, driven by operating losses and investing activities, partially offset by a $4.9 million equity raise in March 2009 and the release of $11.75 million in restricted cash following the settlement of the Avecia Acquisition.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Financing (July 2009): Following the reporting period, the company completed a private placement issuing $19.3 million in new convertible notes and warrants. Proceeds were used to repay $5.5 million of old notes and fully repay the senior secured credit facility.
- Avecia Settlement: In June 2009, the company settled obligations with Avecia Biologics, paying $7.0 million in deferred consideration and expensing a $3.0 million cancellation fee. This terminated the letter of credit requirement, releasing restricted cash.
- Operational Transition: The company is transitioning manufacturing and development activities for SparVax from the UK to the U.S. to comply with a contract transfer from NIAID to BARDA. The UK workforce and lease are expected to be terminated by June 30, 2010.
- Key Risks:
- Government Dependence: Substantially all revenue is derived from U.S. government contracts. There is no assurance of future awards, specifically regarding the pending RFP-BARDA-08-15 for the SparVax vaccine.
- Liquidity: The company has a history of losses and negative cash flow. While management believes current resources plus the July 2009 financing will fund operations through the end of 2010, future funding is not guaranteed.
- Regulatory & Manufacturing: Reliance on the "Animal Rule" for FDA approval and the need to transfer manufacturing to a new U.S. contract manufacturer present significant execution risks.
Investor Verification Checklist
- Contract Award Status: Verify the status of the RFP-BARDA-08-15 award for the SparVax vaccine, which is critical for future revenue and funding.
- Debt Obligations: Confirm the terms and repayment schedule of the $19.3 million in new convertible notes issued in July 2009.
- Manufacturing Transfer: Monitor the progress of technology transfer for SparVax to the new U.S.-based contract manufacturer and associated costs.
- UK Exit Costs: Track the actual costs incurred related to the termination of UK operations and workforce by the projected June 2010 deadline.
- Liquidity Runway: Assess whether the company's cash burn rate aligns with management's projection of funding through the end of 2010.